UGN-201

DRUG2 trials

Sponsors

M.D. Anderson Cancer Center, UroGen Pharma Ltd.

Conditions

BladderBladder CancerCarcinoma in Situ of BladderNMIBCNon-muscle Invasive Bladder CancerUrothelial Carcinoma BladderUrothelial Carcinoma Recurrent

Phase 1

A Window of Opportunity Phase I Study of UGN-201 in Patients With Bladder Cancer Undergoing Radical Cystectomy Protocol #: 2021-0630

Active, not recruitingNCT05055050

M.D. Anderson Cancer CenterBladder, Bladder Cancer

Start: 2022-01-24End: 2026-08-31Target: 10Updated: 2026-08-06

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

CompletedNCT05375903

UroGen Pharma Ltd.Bladder Cancer, Carcinoma in Situ of Bladder, NMIBC +3

Start: 2022-06-01End: 2026-01-09Updated: 2026-01-14